GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · IEX Real-Time Price · USD
11.82
-0.18 (-1.50%)
At close: Apr 24, 2024, 4:00 PM
11.83
+0.01 (0.08%)
After-hours: Apr 24, 2024, 6:59 PM EDT

Company Description

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.

The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.

GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

GeneDx Holdings Corp.
GeneDx Holdings logo
Country United States
Founded 2017
Industry Health Information Services
Sector Healthcare
Employees 1,000
CEO Ms. Katherine A. Stueland

Contact Details

Address:
333 Ludlow Street, North Tower, 8th Floor
Stamford, Connecticut 06902
United States
Phone 617 780 8742
Website genedx.com

Stock Details

Ticker Symbol WGS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818331
ISIN Number US81663L2007
Employer ID 85-1966622
SIC Code 8000

Key Executives

Name Position
Katherine A. Stueland President, Chief Executive Officer and Director
Kevin Feeley Chief Financial Officer
Karen Ponchner Senior Vice President and Head of Operations
Eric Olivares Ph.D. Chief Product and Technology Officer
Devin K. Schaffer J.D., M.B.A. General Counsel
Paul Kruszka M.D. Chief Medical Officer
Melanie Duquette Chief Growth Officer
Sabrina Dunbar Chief of Staff

Latest SEC Filings

Date Type Title
Feb 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 23, 2024 10-K Annual Report
Feb 20, 2024 8-K Current Report
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report
Nov 17, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 15, 2023 144 Filing
Nov 3, 2023 10-Q Quarterly Report
Oct 30, 2023 8-K Current Report
Aug 8, 2023 10-Q Quarterly Report